People
John Orloff and Brian Goff spoke with BioSpace about Alexion and new trends and developments the company is reporting.
With key investors upset about Allergan’s share price, Saunders pointed to five potential drugs on the market within the next 18 months.
Three Researchers Awarded $250,000 Each to Advance Independent Research in Cardiac Diseases
In this interview, Dr. Christopher J. Schaber, President and CEO, discusses the Company with The Wall Street Analyzer.
Factory-CRO Group, a leading global contract research organization, is pleased to announce Sapna Hornyak as its new president and CEO and the appointment of Nick Thornton to chairman of its board of directors.
Although the advent of cell and gene therapies is revolutionizing medicine, it is arguable that the therapies that have been approved to date in this area aren’t living up to expectations.
There are several lessons that companies and investors can learn from the collapse of Theranos, and one of the key takeaways is in the area of transparency.
Invitrocue Limited is pleased to provide its Appendix 4C cash flow statement for the quarter ended March 31, 2019 and to announce the appointment of Dr Sharifuddin Abdul Wahab as Global Insurance Advisor.
NOXXON Pharma N.V. announced the appointment of Dr. Maurizio PetitBon, member of the Supervisory Board since September 2016, as Chairman of NOXXON’s Board.
The industry was shaken up when Tokyo-based Eisai and its collaboration partner, Biogen, announced they were abandoning huge swaths of their Alzheimer’s program related to aducanumab in late March.
PRESS RELEASES